Breaks Categories: Analyst Alerts

WednesdayJul 26, 2017 2:44 pm

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on Alternate Health Corp. (AHGIF)

SeeThruEquity has initiated coverage with a price target of $4.65 on shares of Alternate Health Corp. (OTCQB: AHGIF) stock. Among other highlights, the analyst noted that the company’s San Antonio-based laboratory subsidiary provides an established revenue stream, which stands out compared to many public companies in the cannabis space. The laboratory was responsible for approximately $3.7 million in first quarter 2017. This profitable business is also viewed as a strategic asset in establishing relationships with health care providers. Additionally, the analyst noted the company’s technology solutions: VIP Patient™ Health Record Management System, a cloud-based electronic medical records system, and CanaCard…

Continue Reading

TuesdayJul 18, 2017 12:50 pm

NetworkNewsBreaks – SeeThruEquity Updates Great Basin Scientific, Inc. (GBSN) Coverage

SeeThruEquity has updated its coverage on Great Basin Scientific, Inc. (OTCQB: GBSN) stock following the company’s news that it has received FDA 510(k) clearance for its new Stool Bacterial Pathogens Panel (SBPP) for foodborne illness. FDA clearance now allows the company to begin actively marketing SBPP to its current customer base of over 230 hospitals and labs, as well as new customers. Management expects the SBPP to be the flagship test moving forward. SeeThruEquity’s previously issued price target of $1.00 on shares of the company’s stock remains unchanged. For more information, visit www.gbscience.com About Great Basin Scientific Great Basin Scientific is…

Continue Reading

TuesdayJul 18, 2017 12:48 pm

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on PURE Bioscience, Inc. (PURE)

SeeThruEquity has initiated coverage with a price target of $2.45 on shares of PURE Bioscience, Inc. (OTCQB: PURE) stock. Last year, the FDA increased regulatory scrutiny through finalizing the Food Safety Modernization Act, which the analyst believes will benefit PURE by pushing more companies to seek superior food safety solutions. Looking forward, the company is anticipated to increase revenues through new customer acquisitions, commercialization of PURE Control®, and entry into new markets. The analyst expects these catalysts to increase revenues by 403% YOY to $9.7 million in full year 2018. For more information, visit www.purebio.com About PURE Bioscience, Inc. PURE Bioscience,…

Continue Reading

WednesdayJul 12, 2017 2:01 pm

NetworkNewsBreaks – NeuroVive Pharmaceutical AB (NEVPF) Receives Coverage Update, Increased PT by SeeThruEquity

SeeThruEquity has issued a company update and increased price target of SEK 8.50 ($0.98) on shares of NeuroVive Pharmaceutical AB’s (OTCQX: NEVPF) stock. The Sweden-based clinical stage biotechnology company continues to advance its lead candidate, NeuorSTAT® for neuro-protective properties in moderate to severe Traumatic Brain Injury (TBI). The company reported encouraging data from both a study in the U.S. at the University of Pennsylvania, which showed a significantly reduced volume of brain injury, and the CHIC phase 2a clinical trial at Copenhagen University Hospital in Denmark, which met its main objectives of demonstrating safety and characterizing the pharmacokinetic profile of…

Continue Reading

WednesdayJul 12, 2017 2:00 pm

NetworkNewsBreaks – SeeThruEquity Issues Update on Great Basin Scientific, Inc. (GBSN)

SeeThruEquity has updated its coverage and issued a price target of $1 on shares of Great Basin Scientific, Inc.’s (OTCQB: GBSN) stock, noting several corporate highlights. Great Basin Scientific has reported growth of over 120% in its pipeline after recently expanding its menu of molecular tests, which the analyst noted also drives opportunity for the company. The planned expansion moves the number of assays to five with a sixth molecular test currently awaiting FDA clearance. For more information, visit www.gbscience.com About Great Basin Scientific Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The company is…

Continue Reading

WednesdayJul 12, 2017 1:58 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Q BioMed, Inc. (QBIO)

In a recent update on Q BioMed, Inc. (OTCQB: QBIO), SeeThruEquity noted, among other topics, that the biomedical acceleration and development company’s FDA-approved radiopharmaceutical agent, SR89 (Strontium Chloride), is ahead of schedule and “revenue ready.” Q BioMed has initiated production of SR89 for the treatment of metastatic bone cancer and expects a commercial launch later this year. The company previously estimated it could generate more than $1 million in sales in its first year of commercialization, reaching more than $10 million in sales within 3-5 years. The SeeThruEquity analyst notes that SR89 has the potential for additional indications and a larger therapeutic…

Continue Reading

WednesdayJul 05, 2017 11:45 am

NetworkNewsBreaks – Aegis Capital Issues ‘Buy’ Rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital has issued a ‘Buy’ rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), citing the company’s recent filing of a Post-Grant Review (PGR) against Incyte Corporation’s (NASDAQ: INCY) U.S. Patent No. 9,662,335. The patent includes claims relating to Janus kinase inhibitors (JAKs), which affects Concert's deuterated ruxolitinib CTP-543, an oral JAK 1/2 inhibitor designed to treat alopecia areata. The analyst believes that the PGR process could resolve IP issues early, and the company appears confident in its case. For more information, visit www.concertpharma.com About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated…

Continue Reading

WednesdayJul 05, 2017 11:43 am

NetworkNewsBreaks – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) Has “Buy” Rating Reiterated at Aegis Capital

Aegis Capital reiterated a ‘Buy’ rating and price target of $41 on shares of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) following the company’s recent report that eptinezumab met the primary and key secondary endpoints in PROMISE 1, a phase 3 pivotal clinical trial evaluating patients with frequent episodic migraine. The analyst noted that this positive news pushes the company one step closer to FDA approval for eptinezumab. Additionally, an upcoming catalyst for the company is the PROMISE 2 data expected in the first half of 2018. For more information, visit www.alderbio.com About Alder BioPharmaceuticals Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…

Continue Reading

ThursdayJun 29, 2017 12:16 pm

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on Earth Science Tech, Inc. (ETST)

SeeThruEquity has initiated coverage and a price target of $4.12 on Earth Science Tech, Inc. (OTC: ETST). Among other highlights, the analyst noted the company’s strong product pipeline, which includes a series of CBD-based nutraceutical and pharmaceutical products anticipated to be launched in the second quarter of 2017 and early 2018. Additionally, the company’s recent launch of new flavored CBD oil (Orange Blossom), organic chocolate CBD line, and pet CBD is expected to boost revenues for this year. For more information, visit www.earthsciencetech.com About Earth Science Tech, Inc. (ETST) Earth Science Tech provides high quality, purity, and full spectrum High…

Continue Reading

WednesdayJun 21, 2017 12:32 pm

NetworkNewsBreaks – Trevena, Inc. (NASDAQ: TRVN) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $14 on shares of Trevena, Inc. (NASDAQ: TRVN) following the company’s recent management meetings. Among other highlights from the meetings, the analyst noted Trevena’s completion of pre-launch commercial activity. Trevena has completed interviews with around 140 pharmacy directors and 40 anesthesiologists regarding Olinvo. As for the investors' concerns regarding the launch of Olinvo in the U.S., the analyst believes it is worth launching and could be a product with peak year revenue in the range of $200 million-$300 million. For more information, visit www.trevena.com About Trevena  Trevena, Inc. is…

Continue Reading